Metabolic · Dosing reference

Exenatide dosage

Dosing as the FDA label states it, how long trials ran, and the arithmetic for working with vials.

FDA-approvedAHuman trial evidenceFDA label

Full research page Cycle-length evidence Compare Prefer Amiravo on Google

Regulatory status: FDA-approved
Human amounts: 5 micrograms twice daily to start; may increase to 10 micrograms twice daily after 1 month based on clinical response
Route studied: Subcutaneous injection
Frequency: Twice daily, within 60 minutes before the morning and evening meals
Half-life: Mean terminal half-life 2.4 hours
Evidence grade: Grade A · Human trial evidence
Vial sizes on the market: Not recorded
Other forms seen: —

What Exenatide is

Exenatide is a synthetic 39-amino-acid GLP-1 receptor agonist originally identified in Gila monster venom, FDA-approved (initial U.S. approval 2005) as a twice-daily injection for glycemic control in adults with type 2 diabetes.

Exenatide binds and activates the human GLP-1 receptor in vitro, increasing glucose-dependent insulin synthesis and secretion through cAMP and other intracellular pathways ^1. Pharmacodynamics It enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon secretion and slows gastric emptying ^1. Pharmacokinetics After subcutaneous injection, median time to peak is 2.1 hours; clearance… How it works →

Key evidence

DeFronzo et al., Diabetes Care · 2005 · Humans (adults with type 2 diabetes on metformin)
HbA1c -0.78% (10 micrograms) and -0.40% (5 micrograms) versus +0.08% with placebo; body-weight change -2.8 and -1.6 kg; GI events most frequent ^4. ⁴
Holman et al., N Engl J Med (EXSCEL, NCT01144338) · 2017 · Humans (14,752 adults with type 2 diabetes)
MACE 11.4% versus 12.2% (HR 0.91, 95% CI 0.83-1.00): noninferior, not superior; no significant differences in pancreatitis, pancreatic cancer or medullary thyroid carcinoma ^5. ⁵
Vijiaratnam et al., Lancet (Exenatide-PD3) · 2025 · Humans (194 people with Parkinson's disease)
MDS-UPDRS III off-medication scores worsened by 5.7 versus 4.5 points (p=0.47); no evidence of disease modification ^6. ⁶

All studies on the research page

Schedules by time period

Label regimens and laid out week by week. Each bar is what the label states or what investigators gave participants; none is a recommendation.

FDA label

Byetta / exenatide injection (FDA label): dosing ¹

Adults with type 2 diabetes

Exenatide twice daily

SC · twice daily before meals

Week-by-week table

Period	Amount
Weeks 0–4	5 mcg
Weeks 4–onward	10 mcg (maintenance)

Escalation to 10 micrograms is based on clinical response.

Dosing as stated on the FDA label

Initiate at 5 micrograms subcutaneously twice daily at any time within the 60-minute period before the morning and evening meals (or before the two main meals of the day, about 6 hours or more apart); do not administer after a meal ^1.
Based on clinical response, the dose can be increased to 10 micrograms twice daily after 1 month of therapy, to reduce the risk of GI adverse reactions ^1.
Coadministration with other exenatide-containing products is not recommended. Administration instructions are set out in the label and are not reproduced here ^1.

How long did human studies run?

No human study durations are recorded for Exenatide.

Cycle-length evidence for Exenatide

Side effects reported in studies

Nausea
44% versus 18% placebo · Three 30-week add-on trials to metformin and/or sulfonylurea (n=963 vs 483) ¹
Vomiting
13% versus 4% · Same trials ¹
Diarrhea
13% versus 6% · Same trials ¹
Feeling jittery
9% versus 4% · Same trials ¹
Dizziness
9% versus 6% · Same trials ¹
Headache
9% versus 6% · Same trials ¹
Dyspepsia
6% versus 3% · Same trials ¹
Hypoglycemia with a sulfonylurea
14.4% (5 micrograms) and 35.7% (10 micrograms) versus 3.3% placebo; no severe events · 30-week add-on to sulfonylurea trial ¹

Full adverse-event data

Supplies and handling

Lyophilized vial
Sealed vial with the freeze-dried cake. Check the label, lot and the certificate of analysis before opening.
Sterile diluent
The diluent named on the product documentation. Bacteriostatic water contains benzyl alcohol; sterile water does not.
Graduated syringes
Sized to the volume being measured. U-100 insulin syringes are graduated in units where 100 units = 1 mL.
Alcohol prep pads
For wiping vial stoppers before each puncture.
Nitrile gloves
Clean gloves for aseptic handling.
Sharps container
Puncture-resistant container for used needles.

Step-by-step reconstitution guide Storage and transport accessories

Storage

Follow the current label for approved products; peptide solutions of this kind are generally refrigerated and protected from light. Research materials should be handled per the supplier's documentation.

Lyophilized (unmixed) vials: typically stored cold and dry, away from light, as the documentation directs. Many are stable longer frozen.
Reconstituted vials: typically refrigerated (about 2–8 °C), protected from light and not frozen.
Bacteriostatic water contains benzyl alcohol, which inhibits bacterial growth in multi-use vials; sterile water has no preservative.

Handling mistakes and troubleshooting

Added the wrong volume of diluent: The concentration changes, not the amount of compound in the vial. Recalculate with the volume actually added and relabel the vial.
Shook the vial and it foamed: Let it settle in the refrigerator. Foam is a sign of agitation; some peptides aggregate when shaken. Note it on the label.
The solution is cloudy or has particles: Do not use it. Cloudiness can indicate incomplete dissolution, contamination or degradation. Record the lot and contact the supplier with the certificate of analysis.
The powder cake looks melted or shrunken before reconstitution: This can indicate the vial was exposed to heat or moisture. Record the lot and condition on arrival.
Liquid sprayed back when the needle was removed: Pressure built up in the vial. Withdraw a small volume of air while adding diluent to keep pressure neutral.

Regulatory status

Status: FDA-approved (initial U.S. approval 2005). As of 2026-10-24, Drugs@FDA lists Byetta (NDA 021773), Bydureon (NDA 022200) and Bydureon BCise (NDA 209210) as discontinued, while a generic exenatide injection label (Amneal) was updated on DailyMed in 2026; the openFDA record lists that ANDA's marketing status as discontinued, so current U.S. availability should be confirmed ^1,2,3.
United States (FDA): FDA-approved (initial U.S. approval 2005). Drugs@FDA (openFDA, data updated 2026-10-23) lists Byetta, Bydureon and Bydureon BCise as discontinued; a generic exenatide injection label (Amneal, ANDA 206697) was updated on DailyMed in 2026 ^1,2,3.
Sport (WADA): GLP-1 receptor agonists were not mentioned on the WADA 2026 Prohibited List page reviewed ^8.

Status varies by country and changes over time. How we describe regulatory status.

Exenatide compared with related compounds

Compound	Status	Evidence	Human amounts	Half-life
Exenatide	FDA-approved	A	FDA label	Mean terminal half-life 2.4 hours
Pentadeca arginate (PDA)	Not approved — research use only	—	None established	—
PEA	Not approved — research use only	A	None established	—
Tesofensine	Investigational	B	Trial doses	About 234 hours (M1 metabolite about 374
Mazdutide	Approved outside the US	A	Trial doses	150.9 to 403.5 hours (phase 1b in overwe
Cagrilintide	Investigational	A	Trial doses	159 to 195 hours (phase 1b, co-administe

Frequently asked questions

What doses of Exenatide have been studied in humans?

Exenatide is FDA-approved, so the label states the dosing for the approved product. This page quotes it, with citations. It does not apply to research-grade material.

Is there an established Exenatide cycle length?

No. We found no human studies that report treatment duration for Exenatide.

How much bacteriostatic water should be added to a Exenatide vial?

There is no compound-specific volume. The diluent volume only sets the concentration: concentration = mass in the vial ÷ volume added (for example, 10 mg in 2 mL gives 5 mg/mL). The calculator on this page shows the arithmetic for any combination.

How many units is a given amount on an insulin syringe?

On a U-100 syringe, 100 units = 1 mL. Units for an amount = amount ÷ (concentration per unit). The calculator converts any amount you enter at the concentration you choose; a unit is a volume mark, not an amount of compound.

What is the half-life of Exenatide?

Mean terminal half-life 2.4 hours

Is Exenatide FDA-approved?

FDA-approved. FDA-approved (initial U.S. approval 2005). As of 2026-10-24, Drugs@FDA lists Byetta (NDA 021773), Bydureon (NDA 022200) and Bydureon BCise (NDA 209210) as discontinued, while a generic exenatide injection label (Amneal) was updated on DailyMed in 2026; the openFDA record lists that ANDA's marketing status as discontinued, so current U.S. availability should be confirmed ^1,2,3.

References

BYETTA (exenatide) injection, for subcutaneous use, prescribing information (DailyMed, effective 09/2025) FDA label (DailyMed). 2025
Exenatide injection (Amneal), prescribing information (DailyMed, effective 05/2026) FDA label (DailyMed). 2026
Drugs@FDA (openFDA) application records for exenatide (NDA 021773, NDA 022200, NDA 209210, ANDA 206697) U.S. FDA. 2026
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care. 2005
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL) N Engl J Med. 2017
Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial Lancet. 2025
Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom J Biol Chem. 1992
World Anti-Doping Agency Prohibited List 2026 (online version) WADA. 2026
PubChem compound record for exenatide PubChem. 2026

Last reviewed October 24, 2026 by the Amiravo editorial team. Editorial policy · Report an error